Sutro Biopharma reports third quarter 2025 financial results with $167.6 million in cash and securities
Sutro Biopharma Inc. reported cash, cash equivalents, and marketable securities of $167.6 million as of September 30, 2025, compared to $388.3 million as of September 30, 2024. The company expects its current cash position, together with anticipated near-term milestone payments and cost reductions from a recent organizational restructuring, to provide a cash runway into at least mid-2027. Recent business developments include the FDA clearance of the Investigational New Drug application for STRO-004, with plans to dose the first patient before year-end, and the presentation of new preclinical data on dual-payload ADCs at scientific conferences. The restructuring aims to prioritize advancement of ADC programs and research and development collaborations.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sutro Biopharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9570765-en) on November 06, 2025, and is solely responsible for the information contained therein.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。